drugset
Drugs / UV1
last change May 2026 re-read 2 minutes ago

UV1

also known as UV1 vaccine

Peptide targets TERT

Developed for
melanoma · non-small cell lung carcinoma · head and neck squamous cell carcinoma · lung cancer · malignant pleural mesothelioma · ovarian cancer · prostate cancer
Investigated by
Ultimovacs ASA · Oslo University Hospital · Alesund Hospital · Apotheke der Universitätsmedizin der Johannes Gutenberg-Universität Mainz (Germany) · Arbeitsgemeinschaft Gynaekologische Onkologie Austria · Axel Hinke. CCRC Cancer Clinical Research Consulting (Düsseldorf, Germany
+18 more · Belgian Gynaecological Oncology Group · Bristol-Myers Squibb · Dutch Gynaecological Oncology Group · European Network of Gynaecological Oncological Trial Groups (ENGOT) · Haukeland University Hospital · Hellenic Cooperative Oncology Group · Helse Fonna · Helse Forde · Helse Nord-Trøndelag HF · Helse Stavanger HF · Martin-Luther-University Halle-Wittenberg · Nordic Society of Gynaecological Oncology - Clinical Trials Unit · North Eastern German Society of Gynaecological Oncology · St. Olavs Hospital · University Hospital of North Norway · University Hospital, Akershus · Vestre Viken Hospital Trust · Åslaug Helland

Trials 9 · a red edge is where a trial was stopped

today NCT05344209 · Ph 2 NCT04742075 · Ph 2 NCT05075122 · Ph 2 NCT04382664 · Ph 2 NCT04300244 · Ph 2 NCT03538314 · Ph 1 NCT02275416 · Ph 1/2 NCT01784913 · Ph 1/2 NCT01789099 · Ph 1/2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03538314 Jul 2018 → Oct 2022 melanoma Ultimovacs ASA Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT02275416 Feb 2015 → Oct 2016 melanoma Ultimovacs ASA Completed No outcome recorded
Phase 1/2 NCT01784913 Apr 2013 → Jul 2015 prostate cancer Ultimovacs ASA Completed No outcome recorded
Phase 1/2 NCT01789099 Apr 2013 → Feb 2016 non-small cell lung carcinoma Ultimovacs ASA Completed No outcome recorded
Phase 25 trials
Phase 2 NCT05344209 Aug 2022 → Jul 2025 overdue non-small cell lung carcinoma Vestre Viken Hospital Trust Recruiting No outcome recorded
Phase 2 NCT04742075 Dec 2021 → May 2026 overdue ovarian cancer Nordic Society of Gynaecological Oncology - Clinical Trials Unit Active not recruiting No outcome recorded
Phase 2 NCT05075122 Aug 2021 → Aug 2024 head and neck squamous cell carcinoma Martin-Luther-University Halle-Wittenberg Unknown No outcome recorded
Phase 2 NCT04382664 May 2020 → Jan 2024 melanoma Ultimovacs ASA Completed No outcome recorded
Phase 2 NCT04300244 May 2020 → Mar 2025 overdue lung cancer, malignant pleural mesothelioma Åslaug Helland Active not recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as UV1 “UV1” NCT02275416 ↗
9

NCT05075122 ↗

NCT01784913 ↗

NCT04382664 ↗

NCT01789099 ↗

NCT04300244 ↗

NCT02275416 ↗

NCT04742075 ↗

NCT03538314 ↗

NCT05344209 ↗
Known as UV1 vaccine “The UV1 vaccine and GM-CSF will be given before and between treatments of ipilimumab.” NCT02275416 ↗
Modality Peptide “UV1 (a therapeutic synthetic peptide vaccine)” NCT01784913 ↗
Route Other “UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.” NCT01784913 ↗
Target TERT “The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT).” NCT04300244 ↗